title: Direct-to-consumer advertising of prescription medicines: a counter argument.
abstract: Direct-to-consumer advertising of prescription-only medicines is currently only permitted in the USA and New Zealand. Barbara Mintzes and Dee Mangin provide their case against direct-to-consumer advertising of prescription medicines, arguing that its wider introduction would lead to a 'Pharma-knows-best' culture.
authors.affiliation: Therapeutics Initiative, University of British Columbia, 2176 Health Services Mall, Vancouver, BC, V6T 1Z3, Canada. barbara.mintzes@ti.ubc.ca
authors.forename: Barbara
authors.initials: B
authors.lastname: Mintzes
authors.forename: Dee
authors.initials: D
authors.lastname: Mangin
mesh_terms: D000329:Advertising; D011307:Drug Prescriptions / Q000191:economics*; D006333:Heart Failure / Q000209:etiology; D007783:Lactones / Q000009:adverse effects; D011209:Power, Psychological; D011634:Public Health; D013450:Sulfones / Q000009:adverse effects
chemical_list: D007783:Lactones; D013450:Sulfones; C116926:rofecoxib